A Single‐Cell‐Derived Proliferative Signature Is Associated With Progression‐Free Survival During Immunotherapy and Sunitinib Treatment in Clear Cell Renal Cell Carcinoma
Genetics Research · 2026-01 · 2026 (1)
DOI: 10.1155/genr/4050985 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genetics Research, online erschienen am 09.11.2026. Verfasst von Zeyu Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tianjin First Central Hospital, Tianjin, 300071, China, tj-fch.com. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Sunitinib, Kidney Neoplasms, Immunotherapy. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tianjin Health Science and Technology Project, Tianjin Key Medical Discipline (Specialty) Construction Project, Natural Science Foundation of Tianjin City.
Abstract (Originalsprache)
Background
Resistance to immune checkpoint inhibitors and VEGFR‐targeted agents limits durable disease control in clear cell renal cell carcinoma (ccRCC). We examined a tumour cell proliferative transcriptional programme in relation to treatment response and progression‐free survival (PFS).
Methods
We analysed predominantly unpaired baseline and progression single‐cell transcriptomes from anti‐PD‐1‐treated ccRCC. A fixed 20‐gene signature underwent patient‐adjusted pseudobulk and RNA‐inferred copy‐number analyses. Pretreatment scores were evaluated in 332 patients across four immunotherapy or sunitinib groups from three studies, with established proliferation benchmarks and time‐varying survival analyses.
Results
The discovery comparison included five baseline and six progression patients. All 20 genes, including PLK1, UBE2C and CDC20, retained higher expression in the proliferative cluster after patient adjustment, although its abundance difference did not survive multiple‐testing correction (BH‐adjusted q = 0.164). The score closely tracked G2M ( r = 0.915–0.980), without superior PFS discrimination in the primary benchmark. Inclusive response AUCs were 0.519 for IMmotion150 immunotherapy, 0.569 for IMmotion150 sunitinib and 0.693 for E‐MTAB‐3267. In E‐MTAB‐3267, the age‐ and sex‐adjusted HR was 1.54 per score standard deviation (95% CI 1.13–2.11). The IMmotion150 immunotherapy association weakened over follow‐up; excluding this nonproportional estimate yielded a pooled HR of 1.51 (95% CI 1.24–1.83) in 158 patients.
Conclusion
Single‐cell and bulk transcriptomic analyses connect a proliferative gene‐expression programme with adverse PFS during immunotherapy and sunitinib treatment in ccRCC. The signature provides a compact transcriptional readout of proliferation associated with treatment outcomes, with a stronger relationship to PFS than to objective response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Tianjin First Central Hospital, Tianjin, 300071, China, tj-fch.com.
- The First Central Clinical School, Tianjin Medical University, Tianjin, 300071, China, tijmu.edu.cn.
- Department of Urology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan, 453100, China, xxmu.edu.cn.
- Tianjin First Central Hospital, Nankai University, Tianjin, 300071, China, nankai.edu.cn.
ORCID-Profile: Zeyu Li, Sheng Zeng, Yaowen Li, Qian Liu
Förderung
- Tianjin Health Science and Technology Project
- Tianjin Key Medical Discipline (Specialty) Construction Project
- Natural Science Foundation of Tianjin City
- National Natural Science Foundation of China
Zitieren
APA
Li, Z., Xing, S., Zeng, S., Zhang, Y., Li, Y., & Liu, Q. (2026). A Single‐Cell‐Derived Proliferative Signature Is Associated With Progression‐Free Survival During Immunotherapy and Sunitinib Treatment in Clear Cell Renal Cell Carcinoma. Genetics Research, 2026(1). https://doi.org/10.1155/genr/4050985
Vancouver
Li Z, Xing S, Zeng S, Zhang Y, Li Y, Liu Q. A Single‐Cell‐Derived Proliferative Signature Is Associated With Progression‐Free Survival During Immunotherapy and Sunitinib Treatment in Clear Cell Renal Cell Carcinoma. Genetics Research. 2026;2026(1). doi:10.1155/genr/4050985
BibTeX
@article{Li2026,
author = {Li, Zeyu and Xing, Shaoqiang and Zeng, Sheng and Zhang, Yifei and Li, Yaowen and Liu, Qian},
title = {A Single‐Cell‐Derived Proliferative Signature Is Associated With Progression‐Free Survival During Immunotherapy and Sunitinib Treatment in Clear Cell Renal Cell Carcinoma},
journal = {Genetics Research},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/genr/4050985}
}
EUVIMED